NetworkNewsBreaks

MondayJun 02, 2025 10:15 am

NetworkNewsBreaks – Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Secures Definitive $18.4M DoD Award to Build First Commercial RapidSX(TM) System

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) has finalized the contract for an $18.4 million award from the U.S. Department of Defense to construct its first commercial-scale RapidSX(TM) rare earth separation system and infrastructure at the Strategic Metals Complex (SMC) in Alexandria, Louisiana. This brings total non-repayable funding under Ucore’s existing OT Agreement to $22.4 million. The funds will support engineering, permitting, and construction of a RapidSX(TM) machine and supporting systems capable of processing individual rare earth oxides starting in the second half of 2026. A groundbreaking ceremony was held May 29 with local, state, and federal leaders in attendance. The…

Continue Reading

MondayJun 02, 2025 9:20 am

NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development

Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by scaling Pocono’s output through penetration pricing strategies while advancing development of AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch. A newly formalized partnership with Kindeva Drug Delivery will support shared development costs in exchange for milestone payments as AVERSA moves toward regulatory approval. The product is projected to reach peak U.S. sales of $80 million to $200 million annually. To view…

Continue Reading

MondayJun 02, 2025 9:00 am

NetworkNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Launches Final Spiral Tests Ahead of Montauban Gold-Silver Production

ESGold (CSE: ESAU) (OTCQB: ESAUF) has begun final spiral concentration tests at its Montauban Gold-Silver Project in Quebec, marking a major milestone toward initiating production later this year. Conducted on high-grade railbed material—geologically distinct from the Anacon tailings—the tests target a concentrate representing under 0.3% of total mass while capturing over 50% of contained gold and silver. If successful, the process could enable direct on-site bullion pours, cutting cyanide use and accelerating cash flow. Final lab results are expected within a month, as commissioning of the Montauban plant continues to advance. To view the full press release, visit https://nnw.fm/KBL8r About…

Continue Reading

FridayMay 30, 2025 3:47 pm

NetworkNewsBreaks – MoneyShow to Deliver Actionable Market Strategies for 2025

MoneyShow, a leading producer of live and online financial conferences for investors, traders, and financial advisors, has announced the upcoming “Mid-Year Portfolio Review” on June 17-18, 2025. “The year started on a promising note. But sweeping tariff measures, stubborn inflation, and persistent geopolitical stand-offs have caused considerable turmoil in the financial markets,” said MoneyShow’s Editor-in-Chief Mike Larson. “Our exceptional lineup of speakers will provide in-depth context to these market moves, as well as share highly actionable strategies to optimize portfolios for the remainder of 2025.” To view the full press release, visit https://nnw.fm/UpKUi  About MoneyShow  MoneyShow has a long history…

Continue Reading

FridayMay 30, 2025 3:41 pm

NetworkNewsBreaks – Innovation in Motion: Massimo Group (NASDAQ: MAMO) Launches Fully Digital Retail Platform

Massimo Group (NASDAQ: MAMO) is entering a new growth phase with the launch of a comprehensive digital retail platform. This move is designed to simplify the purchasing process for its UTVs, ATVs, and mini-bikes, while expanding the company’s national sales footprint. “The platform enables customers to complete transactions online, including financing, titling, and checkout, providing a fully digital experience,” reads a recent article discussing the launch. “Massimo expects this shift to unlock greater scalability, reduce sales friction, and drive a significant increase in annual revenue.” To view the full article, visit https://nnw.fm/IQqdO About Massimo Group Massimo Group is a manufacturer and distributor…

Continue Reading

FridayMay 30, 2025 3:02 pm

NetworkNewsBreaks – Adageis’ AI-Powered Insights Aim to Improve Outcomes, Revenue Forecasting

Adageis, a forward-thinking healthcare technology company, has a comprehensive suite of AI-powered solutions aimed at providers shifting from fee-for-service to value-based care. “At the core of the company’s offering is its ProActive Care Platform, which combines predictive analytics with real-time data integration to improve both clinical and financial outcomes,” reads a recent article. “The platform’s Patented Risk Engine (‘PRE’) enables users to forecast revenue based on quality performance metrics and patient care patterns. For providers managing contracts that tie compensation to outcomes, these insights are increasingly important.” To view the full article, visit https://nnw.fm/Adageis About Adageis Adageis is a healthcare…

Continue Reading

FridayMay 30, 2025 11:13 am

NetworkNewsBreaks – Vivakor, Inc. (NASDAQ: VIVK) Declares Special Dividend in Adapti Shares

Vivakor (NASDAQ: VIVK) announced that its Board of Directors has approved a special dividend to be paid in shares of Adapti, Inc., of which Vivakor holds a 13.5% stake. Excluding shares held by its CEO and CFO—who are waiving their rights to participate—eligible shareholders will receive approximately 0.0079 Adapti shares per Vivakor share, a distribution currently valued at $815,000. The record date will be announced in the coming weeks. Adapti, formerly Scepter Holdings, markets products using its AdaptAI platform and became an SEC-reporting company in 2024. To view the full press release, visit https://ibn.fm/ABUxU  About Vivakor, Inc. Vivakor, Inc. is…

Continue Reading

FridayMay 30, 2025 11:07 am

NetworkNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Reports FY 2025 Results with Strong SMS Growth and Platform Expansion

FingerMotion (NASDAQ: FNGR) reported fiscal year 2025 revenue of $35.61 million, down 0.5% year over year, as gains in SMS & MMS were offset by declines in other segments. SMS & MMS revenue surged 206% to $8.17 million, while the Telecommunications Products & Services business fell 17%. Gross profit dropped 28% to $2.76 million, and the company posted a net loss of $5.11 million, a 34% increase from FY 2024. Initial revenue contributions from the DaGe and C2 platforms signaled progress in platform diversification, a key element of the company’s growth strategy moving forward. To view the full press release,…

Continue Reading

FridayMay 30, 2025 10:41 am

NetworkNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Announces Leadership Transition as Montauban Project Nears Production 

ESGold (CSE: ESAU) (OTCQB: ESAUF) announced a strategic leadership transition aligned with its push toward near-term gold and silver production at the Montauban Project in Quebec. As construction advances and the company executes its dual-track strategy—reprocessing historical tailings and district-scale exploration—ESGold is restructuring leadership to support the next phase of operational growth. The company is in advanced discussions with a senior executive to help drive this evolution and expects to share updates soon. Brad Kitchen will no longer serve as President, and ESGold has no plans to appoint a successor to the role at this time. To view the full…

Continue Reading

FridayMay 30, 2025 10:14 am

NetworkNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success in Pediatric Brain Cancer ATRT

Lantern Pharma (NASDAQ: LTRN) reported strong preclinical results for LP-184 in atypical teratoid rhabdoid tumors (“ATRT”), a rare and aggressive pediatric brain cancer. Presented by Dr. Eric Raabe of Johns Hopkins at the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference, the data showed LP-184 significantly improved survival in two mouse models, with one model achieving a 345% increase in median survival (20 to 89 days, p<0.0001). LP-184 demonstrated potent anti-tumor activity across ATRT subtypes, high blood-brain barrier penetration, and a favorable safety profile. Lantern plans to launch a pediatric Phase I trial in late 2025 or early 2026, following the completion…

Continue Reading